Tenax Therapeutics (NASDAQ:TENX) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Tuesday morning,Weiss Ratings reports.

A number of other equities research analysts have also recently commented on the stock. Guggenheim reduced their target price on shares of Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Piper Sandler began coverage on shares of Tenax Therapeutics in a research report on Monday, September 8th. They issued an “overweight” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Up 1.3%

TENX opened at $7.51 on Tuesday. The company has a market cap of $34.25 million, a price-to-earnings ratio of -8.16 and a beta of 1.58. Tenax Therapeutics has a 52-week low of $3.61 and a 52-week high of $8.24. The firm’s fifty day simple moving average is $6.47 and its two-hundred day simple moving average is $6.07.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Wednesday, August 13th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.23. On average, research analysts forecast that Tenax Therapeutics will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Tenax Therapeutics

An institutional investor recently raised its position in Tenax Therapeutics stock. ADAR1 Capital Management LLC increased its position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) by 98.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,741 shares of the specialty pharmaceutical company’s stock after purchasing an additional 34,048 shares during the period. ADAR1 Capital Management LLC owned 1.66% of Tenax Therapeutics worth $450,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.